Copyright Reports & Markets. All rights reserved.

Global Clinical Oncology Next Generation Sequencing (NGS) Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Clinical Oncology Next Generation Sequencing (NGS) Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 NGS Pre-Sequencing
    • 1.4.3 Sequencing
    • 1.4.4 NGS Data Analysis
    • 1.4.5 Primary, Secondary & Tertiary Data Analysis
  • 1.5 Market by Application
    • 1.5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application: 2020 VS 2026
    • 1.5.2 Academic & Clinical Research
    • 1.5.3 Hospitals & Clinics
    • 1.5.4 Pharma & Biotech Entities
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Perspective (2015-2026)
  • 2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Regions
    • 2.2.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Historic Market Share by Regions (2015-2020)
    • 2.2.3 Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Clinical Oncology Next Generation Sequencing (NGS) Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Clinical Oncology Next Generation Sequencing (NGS) Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Market Size
    • 3.1.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue (2015-2020)
    • 3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio
    • 3.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2019
  • 3.3 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
  • 3.4 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
  • 3.5 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Type (2015-2020)
  • 4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
  • 5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
  • 6.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in North America (2019-2020)
  • 6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
  • 6.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
  • 7.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Europe (2019-2020)
  • 7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
  • 7.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

8 China

  • 8.1 China Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
  • 8.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in China (2019-2020)
  • 8.3 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
  • 8.4 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
  • 9.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Japan (2019-2020)
  • 9.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
  • 9.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
  • 10.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

11 India

  • 11.1 India Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
  • 11.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in India (2019-2020)
  • 11.3 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
  • 11.4 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
  • 12.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
  • 12.4 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Illumina
    • 13.1.1 Illumina Company Details
    • 13.1.2 Illumina Business Overview
    • 13.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 13.1.4 Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020))
    • 13.1.5 Illumina Recent Development
  • 13.2 Roche
    • 13.2.1 Roche Company Details
    • 13.2.2 Roche Business Overview
    • 13.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 13.2.4 Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 13.2.5 Roche Recent Development
  • 13.3 Agilent Technologies
    • 13.3.1 Agilent Technologies Company Details
    • 13.3.2 Agilent Technologies Business Overview
    • 13.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 13.3.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 13.3.5 Agilent Technologies Recent Development
  • 13.4 Knome
    • 13.4.1 Knome Company Details
    • 13.4.2 Knome Business Overview
    • 13.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 13.4.4 Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 13.4.5 Knome Recent Development
  • 13.5 Genomatix Software
    • 13.5.1 Genomatix Software Company Details
    • 13.5.2 Genomatix Software Business Overview
    • 13.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 13.5.4 Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 13.5.5 Genomatix Software Recent Development
  • 13.6 GATC Biotech
    • 13.6.1 GATC Biotech Company Details
    • 13.6.2 GATC Biotech Business Overview
    • 13.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 13.6.4 GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 13.6.5 GATC Biotech Recent Development
  • 13.7 Oxford Nanopore Technologies
    • 13.7.1 Oxford Nanopore Technologies Company Details
    • 13.7.2 Oxford Nanopore Technologies Business Overview
    • 13.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 13.7.4 Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 13.7.5 Oxford Nanopore Technologies Recent Development
  • 13.8 Macrogen
    • 13.8.1 Macrogen Company Details
    • 13.8.2 Macrogen Business Overview
    • 13.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 13.8.4 Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 13.8.5 Macrogen Recent Development
  • 13.9 Life Technologies
    • 13.9.1 Life Technologies Company Details
    • 13.9.2 Life Technologies Business Overview
    • 13.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 13.9.4 Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 13.9.5 Life Technologies Recent Development
  • 13.10 DNASTAR
    • 13.10.1 DNASTAR Company Details
    • 13.10.2 DNASTAR Business Overview
    • 13.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 13.10.4 DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 13.10.5 DNASTAR Recent Development
  • 13.11 Exosome Diagnostics
    • 10.11.1 Exosome Diagnostics Company Details
    • 10.11.2 Exosome Diagnostics Business Overview
    • 10.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.11.4 Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.11.5 Exosome Diagnostics Recent Development
  • 13.12 Biomatters
    • 10.12.1 Biomatters Company Details
    • 10.12.2 Biomatters Business Overview
    • 10.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.12.4 Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.12.5 Biomatters Recent Development
  • 13.13 CLC Bio
    • 10.13.1 CLC Bio Company Details
    • 10.13.2 CLC Bio Business Overview
    • 10.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.13.4 CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.13.5 CLC Bio Recent Development
  • 13.14 BGI
    • 10.14.1 BGI Company Details
    • 10.14.2 BGI Business Overview
    • 10.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.14.4 BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.14.5 BGI Recent Development
  • 13.15 Qiagen
    • 10.15.1 Qiagen Company Details
    • 10.15.2 Qiagen Business Overview
    • 10.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.15.4 Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.15.5 Qiagen Recent Development
  • 13.16 Perkin Elmer
    • 10.16.1 Perkin Elmer Company Details
    • 10.16.2 Perkin Elmer Business Overview
    • 10.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.16.4 Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.16.5 Perkin Elmer Recent Development
  • 13.17 Pacific Bioscience
    • 10.17.1 Pacific Bioscience Company Details
    • 10.17.2 Pacific Bioscience Business Overview
    • 10.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.17.4 Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.17.5 Pacific Bioscience Recent Development
  • 13.18 Partek
    • 10.18.1 Partek Company Details
    • 10.18.2 Partek Business Overview
    • 10.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.18.4 Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.18.5 Partek Recent Development
  • 13.19 GnuBIO
    • 10.19.1 GnuBIO Company Details
    • 10.19.2 GnuBIO Business Overview
    • 10.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.19.4 GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.19.5 GnuBIO Recent Development
  • 13.20 Foundation Medicine
    • 10.20.1 Foundation Medicine Company Details
    • 10.20.2 Foundation Medicine Business Overview
    • 10.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.20.4 Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.20.5 Foundation Medicine Recent Development
  • 13.21 Paradigm
    • 10.21.1 Paradigm Company Details
    • 10.21.2 Paradigm Business Overview
    • 10.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.21.4 Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.21.5 Paradigm Recent Development
  • 13.22 Caris Life Sciences
    • 10.22.1 Caris Life Sciences Company Details
    • 10.22.2 Caris Life Sciences Business Overview
    • 10.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.22.4 Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.22.5 Caris Life Sciences Recent Development
  • 13.23 Myriad Genetics
    • 10.23.1 Myriad Genetics Company Details
    • 10.23.2 Myriad Genetics Business Overview
    • 10.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Introduction
    • 10.23.4 Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
    • 10.23.5 Myriad Genetics Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Clinical Oncology Next Generation Sequencing (NGS) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Clinical Oncology Next Generation Sequencing (NGS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Illumina
    Roche
    Agilent Technologies
    Knome
    Genomatix Software
    GATC Biotech
    Oxford Nanopore Technologies
    Macrogen
    Life Technologies
    DNASTAR
    Exosome Diagnostics
    Biomatters
    CLC Bio
    BGI
    Qiagen
    Perkin Elmer
    Pacific Bioscience
    Partek
    GnuBIO
    Foundation Medicine
    Paradigm
    Caris Life Sciences
    Myriad Genetics

    Market segment by Type, the product can be split into
    NGS Pre-Sequencing
    Sequencing
    NGS Data Analysis
    Primary, Secondary & Tertiary Data Analysis
    Market segment by Application, split into
    Academic & Clinical Research
    Hospitals & Clinics
    Pharma & Biotech Entities

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now